Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vatalanib · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxaliplatin/5-FU/LV and PTK787/ZK 222584 |
| 2 | PLACEBO_COMPARATOR | Oxaliplatin/5-FU/LV and placebo |
| Name | Type | Description |
|---|---|---|
| Vatalanib | DRUG | - |
Inclusion criteria: * Patients with metastatic colorectal cancer coming for initial chemotherapy * Documented metastatic colorectal cancer * WHO Performance Status of 0, 1, or 2 * Measurable tumors * Adequate hematologic status, liver and kidney function * Life expectancy greater than 12 weeks * Wr...
Vatalanib is an investigational small molecule being studied for the treatment of colorectal neoplasms, including metastatic colorectal cancer. It was evaluated in Phase 3 clinical trials in combination with oxaliplatin, 5-FU, and leucovorin in patients with previously treated metastatic colorectal cancer. Vatalanib is not approved and remains in clinical development.
Vatalanib is a small molecule that targets vascular endothelial growth factor receptors, which play a role in tumor angiogenesis. By inhibiting these receptors, Vatalanib aims to disrupt the blood supply that tumors need to grow and spread. This mechanism was evaluated in Phase 3 trials for metastatic colorectal cancer.
Vatalanib is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. Novartis sponsored the Phase 3 clinical trials of Vatalanib in patients with metastatic colorectal cancer, which have been completed.
Vatalanib is in Phase 3 clinical development, having completed two Phase 3 trials in metastatic colorectal cancer. These trials were randomized, double-blind, and placebo-controlled. Vatalanib is investigational and has not been approved by regulatory authorities, as it remains in clinical development.
Vatalanib was studied in two completed Phase 3 trials: NCT00056446, which enrolled 855 patients, and NCT00056459, which enrolled 1168 patients. Both trials evaluated Vatalanib combined with oxaliplatin, 5-FU, and leucovorin versus the same chemotherapy regimen without Vatalanib in patients with metastatic colorectal cancer.
Vatalanib is also known by the alternative name PTK787, and both names refer to the same investigational drug. It is a small molecule developed by Novartis AG for the treatment of colorectal cancer. In clinical trials, it was tested in combination with standard chemotherapy for metastatic colorectal cancer.